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Backgrounds: Alzheimer’s disease (AD) is the most common type of dementia, affecting 
millions of older people worldwide. However, pharmacological therapies have not resulted in 
desirable clinical efficacy in the past decades. Non-pharmacological therapies have been 
receiving increased attention to treat dementia in recent years.  
Objectives: This study explores the effects of music therapy on cognitive function and mental 
wellbeing of patients with AD.  
Methods: A total number of two hundred and ninety-eight AD patients with mild, moderate, 
or severe dementia participated in the study. The participants with each grade of severity were 
randomly divided into three groups, which were a singing group, a lyric reading group and a 
control group. These three groups received different interventions for three months. All 
participants underwent a series of cognitive, neuropsychological and activities of daily living 
tests at baseline, three months and six months later.  
Results: In general, our analysis shows that music therapy is more effective for improving 
verbal fluency and for alleviating the psychiatric symptoms and caregiver distress than lyrics 
reading in patients with AD. Stratified analysis shows that music therapy is effective for 
enhancing memory and language ability in patients with mild AD, reducing the psychiatric 
symptoms and caregiver distress in patients with moderate or severe AD. However, no 
significant effect was found for activities of daily living in patients with mild, moderate or 
severe AD. 
Conclusions: This study suggests that music therapy is effective in enhancing cognitive 
function and mental wellbeing and can be recommended as an alternative approach to manage 
AD associated symptoms. 
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Alzheimer’s disease (AD) is a progressive and fatal brain degenerative disease [1]. AD is the 
most common type of dementia in older people, and accounts for 60% of the dementia [2, 3]. 
This cerebral manifestation causes gradual memory loss and decline in cognitive function, 
which progressively affects the activities of daily living (ADL). Patients with AD commonly 
experience neuropsychiatric and behavioral symptoms, which causes substantial distress for 
AD patients and their caregivers [4]. Dementia brings a considerable burden to families and is 
becoming a major challenge for many countries [5]. However, pharmacological therapies 
have not resulted in desirable clinical efficacy, and non-pharmacological therapies have been 
receiving increased attention as an alternative first-line approach for demented people. A 
broad array of such interventions has been developed over the past two decades, such as 
cognitive training [6] , sensory stimulation [7], music therapy [8] , and motor stimulation [9]. 
Music therapy is the application of music and/or its elements (melody, rhythm, harmony, and 
sound) by qualified musical therapists. Participants can passively listen to music or actively 
participate in singing and playing an instrument. Music has been used in the management of 
dementia associated symptoms for many years [10, 11]. Parbery-Clark reported that elderly 
musicians showed greater auditory working memory compared to non-musicians, and 
suggested that musical training may help mitigate the impact of age-related cognition declines 
[12]. By listening to music, patients with AD showed improvement in categorical word 
fluency [13], autobiographical memory [14], and the memory of the lyrics [15]. Furthermore, 
music has been found to facilitate performance during various kinds of cognitive (including 
non-linguistic) tasks [16]. Results from these studies suggest that music therapy could be 
effective for maintaining cognitive function in the elderly with or without dementia. Musical 
interventions have also been used to improve social skills, emotional and neuromotor function 
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[17], and to manage behavioral and psychological symptoms of dementia (BPSD) [11, 18].  
Though the mechanism of music therapy for AD is not fully known, there are some evidence 
and theories to explain its effects. Some studies show that various parts of the brain are 
involved in the music therapy, including subcortical structures such as basal ganglia, nucleus 
accumbens, ventral tegmental area, hypothalamus, and cerebellum [19-21] and cortical 
structures such as medial prefrontal cortex [22] and orbitofrontal cortex [23]. As these areas 
are less affected than medial temporal lobe in AD, music therapy could enhance memory 
function more effectively than speech therapy. Besides, dual coding of lyrics and melody may 
lead to a stronger memory trace, which enhances long-term retention. Satoh, et al (2015) 
conducted a study of singing therapy on patients with AD using the functional magnetic 
resonance imaging (fMRI) scans. The study suggested that singing possibly improves 
cognitive function through organizing a new cognitive strategy [24]. The fMRI analysis 
shows signs of new cognitive activities in the right angular gyrus of the anterolateral region 
and the left lingual gyrus of the occipital lobe during the study period, which suggests that 
singing stimulates the language centre and the logic processing area of the brain [24]. 
Moreover, another study found that singing songs is more effective than reading lyrics, which 
suggests that the brain region for processing music could be redundant in patients with AD 
but singing might stimulate this redundant area allowing reconnection and improving memory 
[25]. The strong connection between singing and speaking suggests that the singing 
component of music therapy enhances linguistic ability and memorization [26].  
However, some scholars argue the effectiveness of music therapy on dementia. A recent 
review reported that music-based therapeutic interventions may have little or no effect on the 
emotional well-being or quality of life, overall behavioral problems and cognition [27]. Thus 
further research with larger sample size needs to be carried out and the relation between the 
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benefits and duration of music therapy should be considered. Therefore this randomized 
controlled trial was conducted to explore the effects of music therapy on cognition, BPSD, 
and ADL of AD patients and their caregiver distress. In order to provide robust evidence of 
music therapy, we followed the participants up for three months to observe how its effects 
would last after completion of the music intervention. In order to further examine if the 
severity of dementia influence the efficacy in different ways, we enrolled AD patients with 
mild, moderate, or severe dementia and the participants with each grade of severity were 
divided into three groups (the singing group, the lyric reading group, and the blank control 
group) randomly. 
MATERIALS AND METHODS 
Participants and procedure 
This study was conducted from Aug 2014 to Dec 2016 in the Center for Cognitive Disorders 
of Beijing Geriatric Hospital, China (Trial registration number: ChiCTR-TRC-14005031, 
http://www.chictr.org.cn). The inclusion criteria were as follows: (a) 65 years old and older, (b) 
with diagnosis of probable AD based on the National Institute of Neurological and 
Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders 
Association (NINCDS-ADRDA) criteria. Participants were excluded if they were  
experiencing any of the following conditions: (a)  hearing difficulty even with wearing 
hearing aids, (b) obvious difficulty in communication, (c) any other conditions which may 
disturb assessments or interventions. Two hundred and ninety eight participants were recruited 
and were assessed with the Clinical Dementia Rating scale (CDR)[28] , which is a rating scale 
for the clinician to characterize the degree of severity of dementia (0 = no dementia, 0.5 or 1 = 
mild dementia, 2 = moderate dementia, 3 = severe dementia). Ninety six of the AD 
participants were with mild dementia (mild AD), 100 with moderate dementia (moderate AD) 
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and 95 with severe dementia (severe AD). The participants with each grade of severity were 
then allocated into three groups randomly (Figure 1). 
Enrollment Randomization and allocation  
Participants were enrolled by dementia specialists in the research team. A non-medical 
research assistant (RA) carried out the randomization, but was not involved in the enrollment, 
assessment, or intervention of the participants. The RA generated random number sequence 
using SAS software for the participants with different severity levels of dementia respectively. 
Then the RA produced sealed envelopes with the serial number outside and group number 
inside and kept the envelopes in a locked drawer which was inaccessible to all the researchers. 
The envelopes were opened sequentially by the RA after baseline assessments and assigned 
participants with different severity levels of dementia to the three groups equally according to 
the group number printed inside the envelopes. Outcome evaluators and data analysts were 
blinded to the group assignment. 
Table 1 illustrates that the Group A is the singing group（defined as music therapy group） 
(total n=100, mild AD n=33, moderate AD n=34, severe AD n=33), Group B is the lyric 
reading group (total n=99, mild AD n=31, moderate AD n=34, severe AD n=34), and Group C 
is the blank control group (total n=99, mild AD n=32, moderate AD n=35, severe AD n=32). 
None of the participants had professional music experience before. 
The study was approved by the scientific and ethical committees of the Beijing Geriatric 





Group A received music therapy by singing or listening to their familiar and favorite songs, in 
which they especially loved in their twenties and thirties. Most of the songs are classic and 
soothing. Group B read the lyrics without the melody of their familiar and favorite songs, and 
they also loved these songs in their twenties and thirties. Both the music therapy and the lyric 
reading therapeutic exercise were practiced in groups with one therapist to five to six 
participants and were carried out twice daily, with one session in the morning and one session 
in the afternoon for 3 months, which lasted 30-40 minutes per session. A three-month follow 
up assessment was carried out after the completion of the intervention. Group C as a control 
group received no special interventions. All three groups received routine medical treatment 
during the study period. This medical treatment included taking conventional medicines 
combining with other daily care and support.  
assessments 
All participants were assessed with the following measurements three times at three months 
intervals. The first assessment referred as t0 took place prior to the commencement of the 
different group intervention, the second assessment as t1 (at 3 months after the 
commencement of different group intervention), and the third assessment as t2 (at 6 months 
after the commencement of different group intervention). The timeline of assessments and 
measures are described in Fig. 1. 
Cognitive Function Assessment 
The Cognitive Function Assessment contains the mini mental state examination (MMSE), the 
World Health Organization University of California-Los Angeles, Auditory Verbal Learning 
Test (WHO-UCLA AVLT) and the semantic verbal fluency test. 
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The MMSE[29] was used to assess the participants’ overall cognitive function. It includes 
multiple domains of cognitive function, comprising of orientation, registration, attention and 
calculation, recall, language and praxis. The maximum achievable score is 30. 
The WHO-UCLA AVLT[30] was used to evaluate the participants’ short-term and long-term 
memory by scoring their performance on immediate recall and delayed recall respectively. 
After learning 15 verbal words, the subjects were required to repeat the words immediately 
and 30 minutes later. 
Language function was assessed with semantic verbal fluency test. It required the participants 
to speak out as many words as possible within 60 seconds from a given category, such as 
animals or vegetables. One-minute animal verbal fluency task was used in this study. 
Neuropsychiatric and Behavioral Symptom Assessment 
The Neuropsychiatric Inventory (NPI) [31] were used to assess neuropsychiatric symptoms in 
AD patients and related caregiver distress. It examines 10 factors of behavioral problems. 
These factors comprise delusions, hallucinations, agitation/aggression, dysphoria, anxiety, 
euphoria, apathy, disinhibition, irritability/lability, and aberrant motor activity. Each factor is 
evaluated in terms of severity (0-3 points) and symptom frequency (0-4 points). The scoring 
index includes factor scores (frequency × severity) and a total score (0–120 points). Higher 
scores represent more severe psychiatric symptoms. The degree of distress on caregivers 
caused by each factor was also assessed and then the sum score was compiled. 
ADL Assessment 
The Barthel Index[32] is an ordinal scale that measures performance on ADL. It uses ten 
variables describing ADL and mobility, including fecal incontinence, urinary incontinence, 
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help needed with grooming, toileting, feeding, transferring, walking, dressing, climbing stairs 
and bathing. Each item is rated with a given number of points assigned to each level or rank. 
Higher scores on the Barthel Index indicate greater independence (total score ranges from 0 to 
100). 
All data for this study were collected by a specially trained medical team of doctors, nurses 
and medical students. A test was performed to all investigators after training and the internal 
consistency coefficient on the evaluation and data collection was above 0.90. 
Primary and secondary outcomes 
The psychometric tools used in this study were analyzed to assess the efficacy of the music 
therapy. The primary study aim was to evaluate the extent to which music therapy impacted 
the language function of AD patients (measured by verbal fluency test score), so the verbal 
fluency test score was selected as the primary outcome. Secondarily, we aimed to evaluate 
changes in NPI score, which measures BPSD. Results of other assessments were also 
analyzed. 
Statistical Analyses 
One-way ANOVA is used to test the difference in the mean values of continuous data between 
three groups. If the test result of ANOVA was significant, a multiple comparison was 
conducted using Fisher’s Least-Significant Difference (LSD) to test the exact group 
difference. The mean difference of two groups is denoted by Δ. The Pearson Chi-square test 
was used to analyze all the categorical data from groups. Data were analyzed using IBM 




During the study period, only 10 out of the 298 participants dropped out from the study, in 
which three participants left the study due to changing residence and seven left due to the 
occurrence of new medical problems (including 4 patients with pneumonia, 3 patients with 
bone fracture). They are three participants from Group A (1 with mild AD, 2 with severe AD), 
three from Group B (1 with mild AD, 2 with severe AD), and four from Group C (1 with mild 
AD, 3 with severe AD). This resulted in a remaining sample of 97 participants in Group A and 
of which 89 participants were able to sing the songs during the whole of the study period and 
8 participants with severe dementia were unable to follow the pace of the therapy at some 
times, 96 participants in Group B, and 95 participants in Group C, which maintained 
relatively balanced sample sizes for comparison groups that were set originally for this study 
(Table 1). The data analysis includes a sample of 288 AD patients.  
The first part of Table 2 presents the descriptive statistics of demographic characteristics and 
medical treatment. There was no significant difference of age, gender, education level and 
medical treatment received during the study period between three groups (P>0.05). 
Analyzing test scores of all participants 
First, we analyzed test scores of 288 patients with AD who completed this study (Group A, 
n=97; Group B, n=96; Group C, n=95). The second part of Table 2 shows the results of 
outcome variables measured by the MMSE, WHO-UCLA AVLT (including immediate recall 
and delayed recall), verbal fluency test, NPI, and Barthel Index at t0, t1 and t2. 
The results of MMSE, WHO-UCLA AVLT, Barthel Index show there is no significant 
difference found in all three assessments of the three groups. 
Verbal Fluency Test  
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In verbal fluency test, there were significant differences among three groups at t1 (5.85±1.04, 
5.92±1.54, 5.48±1.86, F=16.35, P<0.05) and t2 (5.78±1.09, 5.68±1.37, 5.41±1.51, F=14.81, 
P<0.05). Both Group A (Δ=0.37, P<0.05) and Group B (Δ=0.44, P<0.05) scored higher than 
Group C, and there were no statistically significant difference between Group A and Group B 
at t1. Only Group A scored higher than Group C (Δ=0.37, P<0.05), but there were no 
significant difference between Group B and Group C at t2. 
NPI 
In NPI, there were significant differences among three groups at t1 (20.00±12.63, 21.85±11.34, 
24.99±12.35, F=15.66, P<0.05) and t2 (19.36±12.24, 22.08±12.01, 25.22±11.38, F=13.94, 
P<0.05). Both Group A (Δ=－4.99, P<0.05) and Group B (Δ=－3.14, P<0.05) scored lower 
than Group C, and there were no statistically significant difference between Group A and 
Group B at t1. Group A scored lower than both Group B (Δ=－2.72, P<0.05) and Group C 
(Δ=－5.86, P<0.05), but there were no statistically significant difference between Group B 
and Group C at t2. 
 Analyzing test scores of participants with mild AD  
We analyzed test scores of 93 patients with mild AD who completed this study (Group A, 
n=32; Group B, n=31; Group C, n=30). Table 3 shows the results of outcome variables as 
mentioned above.  
The results of MMSE, NPI and Barthel Index show there is no significant difference found in 
all three assessments of the three groups. 
WHO-UCLA AVLT  
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There were significant differences among three groups in the WHO-UCLA AVLT immediate 
recall (7.38±1.45, 6.93±1.34, 6.63±1.26, F=17.42, P<0.05) and delayed recall (6.51±1.52, 
5.88±1.26, 5.57±1.10, F=20.49, P<0.05) at t1. Group A scored higher than Group B and 
Group C in both immediate recall (Δ=0.45, P<0.05; Δ=0.75, P<0.05) and delayed recall 
(Δ=0.63, P<0.05; Δ=0.94, P<0.05) at t1. There were no significant statistical difference 
between Group B and Group C in both immediate recall test and delayed recall test at t1. 
There were no significant difference among three groups in the WHO-UCLA AVLT 
immediate recall or delayed recall at t2. 
Verbal Fluency Test  
There were significant differences among three groups in the verbal fluency test scores at t1 
(8.63±1.94, 8.58±1.75, 7.54±2.03, F=17.56, P<0.05) and t2 (8.45±1.69, 7.89±1.74, 7.43±1.52, 
F=14.37, P<0.05). Both Group A (Δ=1.09, P<0.05) and Group B (Δ=1.04, P<0.05) scored 
higher than Group C and there were no significant statistical difference between Group A and 
Group B at t1; Group A scored higher than Group B (Δ=0.56, P<0.05) and Group C (Δ=1.02, 
P<0.05) and there were no significant statistical difference between Group B and Group C at 
t2.  
Analyzing test scores of participants with moderate AD 
One hundred participants with moderate AD completed this study (Group A, n=34; Group B, 
n=33; Group C, n=33). Table 4 shows the results of outcome variables as mentioned above.  
The results of MMSE, WHO-UCLA AVLT, verbal fluency test, Barthel Index show there is no 




Though there was a trend that Group A scored lower than Group B and Group C at t1 and t2, 
the difference is not statistically significant in NPI score. However, in NPI caregiver distress 
scale, there were significant differences among three groups at t1 (20.73±10.16, 28.90±12.90, 
30.55±19.13, F=18.31, P<0.05) and t2 (21.00±13.63, 29.54±14.86, 31.10±13.14, F=19.88, 
P<0.05). Group A scored lower than Group B (Δ=－8.17, P<0.05; Δ=－8.54, P<0.05) and 
Group C (Δ=－9.82, P<0.05; Δ=－10.1, P<0.05) at t1 and t2. 
Analyzing test scores of participants with severe AD 
Ninety-five participants with severe AD completed this study (Group A, n=31; Group B, n=32; 
Group C, n=32). Table 5 shows the results of outcome variables. 
The results of MMSE, WHO-UCLA AVLT, Verbal Fluency Test, Barthel Index show there is 
no significant difference in all three assessments of the three groups.  
NPI 
In NPI, there were statistically significant differences among three groups at t1 (26.57±10.35, 
31.27±15.36, 35.35±16.45, F=16.51, P<0.05) and t2. (25.96±14.23, 32.43±15.31, 35.43±14.36, 
F=16.23, P<0.05). Group A scored lower than Group B (Δ=－4.7, P<0.05; Δ=－6.47, P<0.05;) 
and Group C (Δ=－8.78, P<0.05; Δ=－9.47, P<0.05) at both t1 and t2. Moreover, in caregiver 
distress scale, there were statistically significant differences among three groups at t1 
(25.12±13.30, 35.64±17.04, 39.57±16.34, F=17.29, P<0.05) and t2 (25.02±13.47, 
36.78±13.47, 40.38±17.31, F=18.13, P<0.05). Group A scored lower than Group B (Δ=－
10.52, P<0.05; Δ=－11.76, P<0.05) and Group C (Δ=－14.45, P<0.05; Δ=－15.36, P<0.05) 




AD is a neurodegenerative disease characterized by cognitive decline, which progressively 
affects the ability of self-maintaining ADL. Impairment in memory is the most common and 
predominant cognitive deficit in AD, but deficits in other cognitive domains (language, 
executive function, and visuospatial skills) are also present. People with AD often experience 
some behavioral disturbances. Up until now there is no effective pharmacological treatment 
that can control the progress of AD disease. Music therapy stimulates various aspects of 
cognitive function and supports emotional, social and physical needs, such as enhancing 
expression of one’s feelings, communication, learning and building new relationships. 
Singing, combines language, music and instinctive human behavior that can enhance 
neurological stimulation[8]. These links produce a positive effect on all of those involved in 
the care or management of dementia and people with dementia[33].  
This study shows that music therapy has positive effect on the ability of immediate and 
delayed word recall in mild AD patients. This result can be explained by the hypothesis that 
singing arouses the region in charge of music processing in the brain may be less utilised in 
patients with AD, which helps improve memory and attention. [34]. However, this effect did 
not sustain longer than 3 months after the intervention completed. This result indicates that 
continuous music therapy could be beneficial to people with AD in a long run or in a longer 
term. 
In a clinical setting, short (i.e., music played as a background in a memory task) and 
long-lasting (i.e., in a music-therapy program) auditory stimulations with music were shown 
to improve both category fluency in a verbal fluency task in older people with or without 
AD[13], and speech content as well as fluency in patients with dementia[35]. In this study, the 
verbal fluency test score of patients with mild AD were higher in the music therapy group 
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than the other two groups after 3 months of intervention and this effect sustained till 3 months 
after the intervention completed. This result shows evidence that music therapy may activate a 
wider range of neural networks with the stimulation of musical melodies, thus enabling 
language functions to be largely maintained and brought into play. Therefore, music therapy 
could be used as speech and language training for people with AD. 
In this study the music therapy was found to be effective on controlling psychiatric and 
behavioral symptoms in patients with severe AD. Its results show that music therapy reduced 
the psychiatric symptoms as well as the caregiver distress for patients with advanced 
dementia, This result is consistent with previous studies; Guetins’s study has confirmed that 
music has a therapeutic effect on anxiety and depression in patients with mild to moderate 
dementia[36], and a Japanese study found that music therapy effectively improved emotional 
and psychiatric symptoms in severe AD patients[37]. Group music interventions may help 
improve social interaction between people with dementia, promoting relaxation and reducing 
levels of agitation[38].  
In conclusion, this randomly controlled trial with 288 participants of AD patients explored 
the effects of music on memory, language and psychiatric conditions and activities of daily 
living in patients with different severities of AD. We found that music therapy can enhance 
memory and language ability in patients with mild AD, and can reduce the psychiatric 
symptoms of the patients with advanced AD as well as the level of the distress encountered 
by their caregivers. The training sessions of singing songs are more effective than reading 
lyrics of the songs, which add further evidence to  the effectiveness of music therapy for 
treating patients with AD.  
There are some limitations of this study. We did not take the participants' familiarity with 
music into consideration in study design, and their ability to sing was not assessed for this 
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research. However none of the participants received professional training in music or singing 
in the past, thus the bias is minimized. Moreover, it showed that even though they were not 
singers, they could all cooperate with singing, listening or reading during the study. 
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Table 1. Composition of the groups  
number Music therapy group 
(Group A) 
Lyrics controlled therapy 
group (Group B) 
Control group 
 (Group C) 
total 
Mild AD 33 (1*) 31 32 (2*) 96(3*) 
Moderate AD 34 34 (1*) 35 (2*) 103(3*) 
Severe AD 33 (2*) 34 (2*) 32  99 (4*) 
total 100 (3*) 99 (3*) 99 (4*) 298 (10*) 
*dropped out  




Table 2. Comparison of demographic characteristics, main medicines received, and 
assessments among groups of participants with Alzheimer's disease (mean±SD) 
 Music therapy 
group 
(Group A, n=97) 
Lyrics controlled 
therapy group 
(Group B, n=96) 
Control group 
(Group C, n=95) 
Age, years 68.9±7.1 70.3±8.3 69.9±7.9 
Male gender, n 40  39 39  
Education, years 6.70±3.01 6.82±3.13 6.71±2.89 
Main medicines    
    Acricept 17 17 18 
    Rivastigmine 15 16 14 
    Memantine 27 25 26 
Atypical antipsychotics 9 11 12 
MMSE score    
t0 13.45±3.66 13.12±3.71 13.22±4.01 
t1 13.34±3.82  12.98±3.99 12.99±3.85 
t2 13.34±4.00 12.83±3.56 12.98±4.15 
WHO-UCLA AVLT 
Immediate recall  
   
t0 5.43±1.41 5.55±1.46 5.77±1.63 
t1 6.06±1.56 5.86±1.71 5.34±1.90 
t2 5.93±1.75 6.15±1.86 5.80±1.55 
Delayed recall     
t0 4.68±1.99 4.72±1.11 4.74±1.20 
t1 4.91±1.06 4.70±1.36 4.64±1.18 
t2 4.73±1.10 4.59±1.42 4.65±1.31 
Verbal fluency test     
t0 5.51±1.11 5.62±1.36 5.53±1.34 
t1 5.85±1.04* 5.92±1.54* 5.48±1.86 
t2 5.78±1.09* 5.68±1.37 5.41±1.51 
NPI score    
t0 26.18±13.25 24.79±12.42 25.62±13.21 
t1 20.00±12.63* 21.85±11.34* 24.99±12.35 
t2 19.36±12.24* 22.08±12.01 25.22±11.38 
Caregiver distress     
t0 31.77±13.64 32.60±15.67 31.95±15.02 
t1 20.71±11.95* 28.41±12.19 30.21±11.54 
t2 20.31±11.44* 29.38±12.82 30.87±12.75 
Barthel Index    
t0 38.83±14.35 38.17±13.61 38.58±10.75 
t1 39.71±13.23 37.54±10.29 38.02±11.44 
t2 39.79±12.94 37.83±11.01 38.52±12.18 
Note: Group A=Music therapy group; Group B= Lyrics controlled therapy; Group C= Control 
group; t0=baseline; t1=3 months; t2=6 months 
* compared with either of the other two groups using one-way ANOVA and LSD or the 
Pearson Chi-square test, P<0.05 
Abbreviations: MMSE, Mini Mental State Examination; WHO-UCLA AVLT, World Health 
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Table 3 Comparison of neuropsychological tests and activities of daily living among  
groups of participants with mild Alzheimer's disease (mean±SD) 
Item 
(mean±SD) 
Group A（n=32） Group B（n=31）  Group C（n=30） 
MMSE score    
t0 17.55±4.21 17.34±4.50 18.09±4.80 
t1 17.64±5.30  17.57±4.1 17.91±3.1 
t2 17.81±4.70 17.59±5.67 17.95±4.70 
WHO-UCLA AVLT 
Immediate recall  
   
t0 6.81±1.40 6.90±1.27 6.67±1.09 
t1 7.38±1.45* 6.93±1.34 6.63±1.26 
t2 7.24±1.42 6.92±1.44 6.61±1.13 
Delayed recall     
t0 5.88±1.34 5.88±1.22 5.77±1.25 
t1 6.51±1.52* 5.88±1.26 5.57±1.10 
t2 6.01±1.63 5.69±1.40 5.55±1.30 
Verbal fluency test     
t0 7.62±1.70 7.68±1.76 7.67±1.76 
t1 8.63±1.94 * 8.58±1.75 * 7.54±2.03 
t2 8.45±1.69 * 7.89±1.74 7.43±1.52 
NPI score    
t0 16.37±11.72 13.22±10.26 15.77±11.73 
t1 13.52±11.63  12.65±10.17 15.14±11.58 
t2 13.01±11.72  12.58±10.03 15.42±9.72 
Caregiver distress     
t0 21.71±12.87 22.18±14.34 19.93±13.56 
t1 16.43±11.90 20.44±10.64 19.85±10.59 
t2 15.02±10.56 21.58±11.27 20.46±13.23 
Barthel Index    
t0 50.33±14.14 49.63±15.01 48.94±11.67 
t1 51.42±16.03 47.75±10.31 49.22±13.56 
t2 52.64±14.41 48.72±12.14 48.86±7.92 
Note: Group A=Music therapy group; Group B= Lyrics controlled therapy; Group C= Control 
group; t0=baseline; t1=3 months; t2=6 months 
* compared with either of the other two groups using one-way ANOVA and LSD or the 
Pearson Chi-square test, P<0.05 
Abbreviations: MMSE, Mini Mental State Examination; WHO-UCLA AVLT, World Health 
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Table 4 Comparison of neuropsychological tests and activities of daily living among groups 
of participants with moderate Alzheimer's disease (mean±SD) 
Item 
mean±SD 
Group A (n=34) Group B (n=33)  Group C (n=33) 
MMSE score    
t0 13.68±2.19 13.51±3.21 13.44±2.75 
t1 13.60±2.34  13.55±4.01 13.43±3.15 
t2 13.27±3.08 13.43±3.65 13.35±3.72 
WHO-UCLA AVLT 
Immediate recall  
   
t0 5.24±2.25 5.19±2.41 6.33±2.01 
t1 6.35±1.92  5.23±1.84 5.23±2.11 
t2 6.24±1.42 6.92±1.44 6.61±1.13 
Delayed recall    
t0 4.10±1.44 4.18±1.87 4.32±1.53 
t1 4.13±1.54 4.18±1.78 4.25±1.64 
t2 4.11±1.70 4.19±1.81 4.25±1.63 
Verbal fluency test     
t0 5.33±1.82 5.68±1.55 5.67±1.80 
t1 5.33±1.93 5.65±1.68 5.54±1.96 
t2 5.40±1.74 5.69±1.75 5.43±1.78 
NPI score    
t0 25.68±12.74 23.95±13.32 24.79±14.14 
t1 20.12±11.53  21.36±11.77 23.89±13.54 
t2 19.33±12.25  20.96±12.52 24.24±11.35 
Caregiver distress      
t0 32.85±15.64 32.74±14.63 33.01±15.26 
t1 20.73±10.16 * 28.90±12.90 30.55±19.13 
t2 21.00±13.63 * 29.54±14.86 31.10±13.14 
Barthel Index    
t0 41.21±13.50 40.42±17.32 41.90±13.74 
t1 41.43±16.25 40.71±12.37 40.24±13.36 
t2 40.61±19.42 41.70±14.16 40.84±17.93 
Note: Group A=Music therapy group; Group B= Lyrics controlled therapy; Group C= Control 
group; t0=baseline; t1=3 months; t2=6 months 
* compared with either of the other two groups using one-way ANOVA and LSD or the 
Pearson Chi-square test, P<0.05 
Abbreviations: MMSE, Mini Mental State Examination; WHO-UCLA AVLT, World Health 
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Table 5 Comparison of neuropsychological tests and activities of daily living among groups of 
participants with severe Alzheimer's disease (mean±SD) 
Item  
(mean±SD) 
Group A (n=31) Group B (n=32)  Group C (n=32) 
MMSE score    
t0 8.97±4.52 8.64±4.54 8.42±4.72 
t1 8.63±5.10  7.96±4.42 7.91±4.65 
t2 8.80±5.34 7.59±4.86 7.95±4.87 
WHO-UCLA AVLT 
Immediate recall 
   
t0 4.20±1.42 4.61±1.27 4.35±1.47 
t1 4.38±1.43 4.63±1.24 4.23±1.22 
t2 4.24±1.63 4.62±1.35 4.21±1.53 
Delayed recall    
t0 4.08±1.42 4.14±1.25 4.20±2.31 
t1 4.11±1.24 4.08±1.35 4.17±1.96 
t2 4.08±1.25 4.07±1.32 4.21±1.14 
Verbal fluency test     
t0 3.54±1.31 3.48±1.34 3.37±1.57 
t1 3.54±1.44 3.63±1.75 3.50±1.55 
t2 3.43±1.41  3.54±1.70 3.49±1.37 
NPI score    
t0 36.87±16.85 36.85±17.63 35.72±15.68 
t1 26.57±10.35* 31.27±15.36 35.35±16.45 
t2 25.96±14.23 * 32.43±15.31 35.43±14.36 
Caregiver distress     
t0 40.96±16.46 42.54±13.75 42.13±14.36 
t1 25.12±13.30 * 35.64±17.04 39.57±16.34 
t2 25.02±13.47 * 36.78±13.47 40.38±17.31 
Barthel Index    
t0 24.35±14.36 24.75±13.14 25.43±12.11 
t1 23.17±15.43 24.38±14.25 25.24±13.20 
t2 25.64±14.34 23.28±14.74 26.44±12.78 
Note: Group A=Music therapy group; Group B= Lyrics controlled therapy; Group C= Control 
group; t0=baseline; t1=3 months; t2=6 months 
* compared with either of the other two groups using one-way ANOVA and LSD or the 
Pearson Chi-square test, P<0.05 
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Abbreviations: MMSE, Mini Mental State Examination; WHO-UCLA AVLT, World Health 
Organization University of California-Los Angeles, Auditory Verbal Learning Test; NPI: 






Fig. 1 Overview of participant flow 
Abbreviations: AD, Alzheimer’s disease; MMSE, Mini Mental State Examination; 
WHO-UCLA AVLT, World Health Organization University of California-Los Angeles, 
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Auditory Verbal Learning Test; NPI, Neuropsychiatric Inventory; ADL, activities of daily 
living.  
